

Report No.: TR 066-046JREV2 Date: June 18, 2024

Receipt Date: 6/4/2024

Analysis Date: 6/18/2024

Page:

Client: Sovereign Health and Performance

Sample Name: BPC-157 (1mg) + TB-4 (10mg) + Ipamorelin (1mg)

Batch#: BPCTHYIPAE124

Report Date: 6/18/2024

Purity

Matrix: Powder

Number of samples: 1


Certificate of Analysis


Purity: 99.0%

Test:

Data File 20240618_BPC157plusTB4plusIpamorelin_re-run.d Sample Name BPC157plusTB4plusIpamorelin_re-run Sample Type Sample Position Instrument Name Instrument 1 **User Name** Aca Method PuritydefaultMS2.m 6/18/2024 12:21:41 PM (UTC-07:00) **Acquired Time** IRM Calibration Status 20211216_PIS7_165and211_quad_SCAN_POS_Nowar taDSDPRWV_neat.m Not Applicable DA Method Comment Sample Group Acquisition Time (Local) 6/18/2024 12:21:41 PM (UTC-07:00) LC 1 Acquisition SW Version 6400 Series Triple Ouadrupole B.09.00 (B9037.0)

Chromatograms





Peak List

Time	Area	%Area
4.849 min.*	33.91	1.0%
5.282 min.**	1229.6	34.7%
5.422 min.***	186.75	5.3%
5.682 min.	2094.98	59.1%
Combined		
purity:		99.0%

Reviewed and Approved By:

Herman Lelie

Note-percent area between compounds is not quantitative due to variable extinction coefficients

Constitution Labs (CL) maintains liability limited to cost of analysis. Interpretation and use of test results are the responsibility of the client. This report relates only to the samples reported above, and may not be reproduced, except in full, without written approval by CL. This is not intended as an endorsement of any product. CL bears no responsibility for sample collection activities or analytical method limitations. Samples are within quality control

criteria and met method specifications unless otherwise noted.

^{*} determined as TB-4 based on retention time

^{**} determined as BPC-157 based on retention time

^{***} determined as Ipamorelin based on retention time